4/A: CytomX Therapeutics Executive Corrects Beneficial Ownership Reporting
SEC Form 4/A
Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics, files an amended Form 4/A to correct errors in the previously reported number of securities acquired and beneficially owned.
Summary
- Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics, filed an amended Form 4/A on February 10, 2025, to correct errors in her original Form 4 filed on February 6, 2025.
- The amendment addresses inaccuracies in the number of securities acquired and the amount beneficially owned, specifically related to restricted stock units (RSUs) and stock options.
- The corrected filing shows Belvin's acquisition of 35,000 RSUs vesting annually from March 15, 2026, and 57,500 RSUs vesting semi-annually from March 15, 2026.
- Belvin also acquired stock options for 150,000 shares vesting monthly from February 4, 2025, and 115,000 shares vesting monthly from February 4, 2025, all at an exercise price of $0.864.
- Following the reported transactions, Belvin beneficially owns 268,148 shares of common stock, including 201,666 RSUs, 150,000 stock options and 115,000 stock options.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't inherently indicate positive or negative sentiment, but accuracy in reporting is generally viewed favorably.
Future Outlook
The document does not contain any specific forward-looking statements or guidance regarding the company's future performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their ownership positions. This filing is an amendment to correct previously reported information.
Stakeholder Impact
- The correction of the Form 4 filing ensures accurate information is available to shareholders regarding insider ownership.
Key Dates
| Date | Description |
|---|---|
| 02/04/2025 | Date of earliest transaction and Vesting Commencement Date for stock options. |
| 02/06/2025 | Date of original Form 4 filing with errors. |
| 02/10/2025 | Date of amended Form 4/A filing. |
| 03/15/2026 | First vesting date for RSUs. |
| 02/03/2035 | Expiration date for stock options. |
Keywords
Form 4/A, CytomX Therapeutics, Beneficial Ownership, Marcia Belvin, RSUs, Stock Options, CTMX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.